Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43426

UPID:
SYNJ1_HUMAN

ALTERNATIVE NAMES:
Synaptic inositol 1,4,5-trisphosphate 5-phosphatase 1

ALTERNATIVE UPACC:
O43426; O43425; O94984; Q4KMR1

BACKGROUND:
The protein Synaptojanin-1, with its alternative name Synaptic inositol 1,4,5-trisphosphate 5-phosphatase 1, is integral to the regulation of phosphoinositide pools in the cell, affecting endocytosis and actin cytoskeleton dynamics. Its enzymatic action on phosphoinositides, such as PIP2, is essential for cellular signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Implicated in early-onset Parkinson disease 20 and Developmental and epileptic encephalopathy 53, Synaptojanin-1's dysfunction highlights its potential as a therapeutic target. The connection of Synaptojanin-1 to these conditions underscores the therapeutic potential of targeting this protein in neurodegenerative and epileptic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.